AFMDQ — Affimed NV Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$12.57m
- €8.28m
Brief: Affimed Announces Proposed Public Offering Of Common Stock
Brief: Affimed Reports New Data For AFM13 From Two Separate Clinical Trials
Brief: Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash
Brief: Affimed reports Q3 loss per share EUR 0.18
Brief: Affimed announces Q3 financial results and corporate update conference call
Brief: Affimed posts Q2 loss of EUR 0.18 per share
Brief: Affimed reports Q4 loss per share EUR 0.16
Brief: Affimed announces closing of public offering of common stock
Brief: Affimed says public offering of 10 mln common shares priced at $1.80/shr
Brief: Affimed announces proposed public offering of common stock
Brief: Affimed, MD Anderson to collaborate on clinical immuno-oncology development
Brief: Affimed NV files to say it may offer and sell its common shares of up to $50 mln
Brief: Affimed reports Q3 loss per share eur 0.31
Brief: Affimed reports financial results for third quarter 2016
Brief: Affimed Q2 loss per share EUR 0.24
Brief: Affimed Q1 loss per share Eur 0.25
Brief: Wellington Management Group LLP reports a 10.71 percent passive stake in Affimed N.V
Brief: Affimed Q4 loss per share eur 0.19
Brief: Affimed posts Q3 loss EUR 0.24/shr